SCHEMBL6473722

SCHEMBL6473722

COc1cc(COCCc2cccc(NS(=O)(=O)C(F)(F)F)c2)ccc1-c1ccc(Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 2/20 0.39
ADRB3 P13945 2/20 0.39
PPARA Q07869 2/20 0.38
PPARG P37231 1/20 0.38
CYP17A1 P05093 1/20 0.36
NR3C1 P04150 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
KCNH2 Q12809 1/20 0.35
KDM1A O60341 1/20 0.35
ROCK2 O75116 1/20 0.35
ROCK1 Q13464 1/20 0.35
CA2 P00918 1/20 0.34
CCNT1 O60563 1/20 0.34
CCNE1 P24864 1/20 0.34
CDK2 P24941 1/20 0.34
CDK9 P50750 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6483863 0.87 PPARA (0.47) PPARAPPARGCYP3A4CYP2D6SLC6A2
SCHEMBL6474334 0.85 CYP3A4 (0.40) CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL6480341 0.85 PPARA (0.39) PPARAPPARGCYP3A4CYP2D6SLC6A2
SCHEMBL6474487 0.85 PPARA (0.39) PPARAPPARGCYP3A4CYP2D6SLC6A2
SCHEMBL6482071 0.83 FFAR1 (0.43) PPARACA2
SCHEMBL6474786 0.81 LTB4R (0.41) PPARAKDM1ACA2
SCHEMBL6474092 0.81 PPARA (0.41) PPARAPPARGCYP3A4CYP2D6SLC6A2
SCHEMBL6482194 0.80 KDM1A (0.43) PPARAPPARGKDM1ACA2
SCHEMBL6479426 0.79 KDM1A (0.43) KDM1ACA2
SCHEMBL6475101 0.79 KDM1A (0.40) PPARAPPARGCYP3A4CYP2D6SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930131-B2 Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) WYETH (US) 2005-08-16 US claimed
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus WYETH (US) 2003-10-30 US claimed
US-6930131-B2 Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) WYETH (US) 2005-08-16 US disclosed
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus WYETH (US) 2003-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus GPR119, INSR, SLC5A1 ADRB1 102/4885ADRB3 216/4885PPARA 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.